Suppr超能文献

速激肽NK1和NK2受体在麻醉豚鼠对阿托品抵抗的结肠推进中的作用

The role of tachykinin NK1 and NK2 receptors in atropine-resistant colonic propulsion in anaesthetized guinea-pigs.

作者信息

Lecci A, Giuliani S, Tramontana M, Giorgio R D, Maggi C A

机构信息

Pharmacology Research Department, Menarini Ricerche s.p.a., Florence, Italy.

出版信息

Br J Pharmacol. 1998 May;124(1):27-34. doi: 10.1038/sj.bjp.0701789.

Abstract
  1. The role of endogenous tachykinins on guinea-pig colonic propulsion was investigated by using potent and selective tachykinin NK1 and NK2 receptor antagonists. Colonic propulsion and contractions were determined by means of a balloon-catheter device, inserted into the rectum of guanethidine (68 micromol kg(-1), s.c., 18 and 2 h before)-pretreated, urethane-anaesthetized guinea-pigs. Propulsion of the device (dynamic model) was determined by measuring the length of the catheter expelled during 60 min filling of the balloon (flow rate 5 microl min(-1)). 2. In control conditions the tachykinin NK1 receptor antagonist SR 140333 (1 micromol kg(-1), i.v.) did not affect either colonic propulsion or the amplitude of contractions. The tachykinin NK2 receptor antagonists MEN 10627 and MEN 11420 (1 micromol kg(-1), i.v.) increased colonic propulsion at 10 min (+120% and 150%, respectively) but at 60 min the effect was significant only for MEN 10627 (+84%). SR 48968 (1 micromol kg(-1), i.v.) did not significantly enhance the colonic propulsion. None of these tachykinin NK2 receptor antagonists modified the amplitude of colonic contractions. In contrast, both atropine (6 micromol kg(-1), i.v., plus infusion of 1.8 micromol h(-1)) and hexamethonium (55 micromol kg(-1), i.v., plus infusion of 17 micromol h(-1)) abolished propulsion (81% and 87% inhibition, respectively) and decreased the amplitude of contractions (68% inhibition for either treatment). 3. In atropine-treated animals (6 micromol kg(-1), i.v., plus infusion of 1.8 micromol h(-1)), apamin (30 nmol kg(-1), i.v.) restored colonic propulsion (+416%) and increased the amplitude of contractions (+367% as compared to atropine alone). Hexamethonium (55 micromol kg(-1), i.v., plus infusion of 17 micromol h(-1)) abolished the apamin-induced, atropine-resistant colonic propulsion (97% inhibition) and reduced the amplitude of the atropine-resistant contractions (52% inhibition). 4. The apamin-induced, atropine-resistant colonic propulsion was inhibited by SR 140333 (-69% at 1 micromol kg(-1)), SR 48968 (-78% at 1 micromol kg(-1)), MEN 11420 (-59% at 1 micromol kg(-1)) and MEN 10627 (-50% at 1 micromol kg(-1)), although the latter effect was not statistically significant. The combined administration of SR 140,333 and MEN 10,627 (1 micromol kg(-1) for each antagonist) almost completely abolished colonic propulsion (90% inhibition). The amplitude of colonic contractions was also reduced by SR 140333 (-42%), SR 48968 (-29%), MEN 11420 (-45%) but not by MEN 10627 (-16%). The combined administration of SR 140333 and MEN 10,627 reduced the amplitude of contractions by 47%. SR 140603 (1 micromol kg(-1), i.v.), the less potent enantiomer of SR 140333, was inactive. 5. In control animals, apamin (30 nmol kg(-1), i.v.) enhanced colonic propulsion (+84%) and increased the amplitude of contractions (+68%), as compared to the vehicle. Hexamethonium (55 micromol kg(-1), i.v. plus infusion of 17 micromol h(-1)) inhibited propulsion (86% inhibition) and decreased the amplitude of contractions (49% inhibition). SR 140333, SR 48968, MEN 11420, MEN 10627, or the coadministration of SR 140333 and MEN 10627 had no effect. 6. In a separate series of experiments, the mean amplitude of colonic contractions was also recorded under isovolumetric conditions through the balloon-catheter device kept in place at 75 mm from the anal sphincter (static model). In control conditions, neither SR 140333 nor MEN 11420 modified the amplitude of contractions. In atropine-pretreated guinea-pigs, SR 140333 and MEN 11420 (0.1-1 micromol kg(-1)) dose-dependently decreased the amplitude of contractions. In apamin- and atropine-pretreated animals, only the highest (1 micromol kg(-1)) dose of SR 140333 or MEN 11420 significantly decreased the amplitude of contractions. The inhibitory potency of atropine (0.3-1 micromol kg(-1)) was similar in apamin-pretreated animals and in controls. 7. It was concluded that, in anaesthetized guinea-pigs, endogenous tachykinins, acting through both NK(1) and NK(2) receptors, act as non-cholinergic excitatory neurotransmitters in promoting an apamin-evoked reflex propulsive activity of the distal colon.
摘要
  1. 通过使用强效且选择性的速激肽NK1和NK2受体拮抗剂,研究了内源性速激肽对豚鼠结肠推进作用的影响。采用球囊导管装置测定结肠推进和收缩情况,该装置插入经胍乙啶(68微摩尔/千克,皮下注射,分别于18小时和2小时前)预处理、氨基甲酸乙酯麻醉的豚鼠直肠中。通过测量球囊在60分钟充盈过程中(流速5微升/分钟)排出的导管长度来确定装置的推进情况(动态模型)。2. 在对照条件下,速激肽NK1受体拮抗剂SR 140333(1微摩尔/千克,静脉注射)对结肠推进或收缩幅度均无影响。速激肽NK2受体拮抗剂MEN 10627和MEN 11420(1微摩尔/千克,静脉注射)在10分钟时增加了结肠推进(分别增加120%和150%),但在60分钟时,仅MEN 10627的作用显著(增加84%)。SR 48968(1微摩尔/千克,静脉注射)未显著增强结肠推进。这些速激肽NK2受体拮抗剂均未改变结肠收缩幅度。相比之下,阿托品(6微摩尔/千克,静脉注射,加1.8微摩尔/小时输注)和六甲铵(55微摩尔/千克,静脉注射,加17微摩尔/小时输注)均消除了推进作用(分别抑制81%和87%),并降低了收缩幅度(两种处理均抑制68%)。3. 在经阿托品处理的动物(6微摩尔/千克,静脉注射,加1.8微摩尔/小时输注)中,蜂毒明肽(30纳摩尔/千克,静脉注射)恢复了结肠推进(增加416%),并增加了收缩幅度(与单独使用阿托品相比增加367%)。六甲铵(55微摩尔/千克,静脉注射,加17微摩尔/小时输注)消除了蜂毒明肽诱导的、阿托品抵抗性的结肠推进(抑制97%),并降低了阿托品抵抗性收缩的幅度(抑制52%)。4. 蜂毒明肽诱导的、阿托品抵抗性的结肠推进受到SR 140333(1微摩尔/千克时抑制69%)、SR 48968(1微摩尔/千克时抑制78%)、MEN 11420(1微摩尔/千克时抑制59%)和MEN 10627(1微摩尔/千克时抑制50%)的抑制,尽管后者的作用无统计学意义。联合给予SR 140,333和MEN 10,627(每种拮抗剂1微摩尔/千克)几乎完全消除了结肠推进(抑制90%)。结肠收缩幅度也受到SR 140333(抑制42%)、SR 48968(抑制29%)、MEN 11420(抑制45%)的降低,但不受MEN 10627(抑制16%)的影响。联合给予SR 140333和MEN 10,627使收缩幅度降低47%。SR 140603(1微摩尔/千克,静脉注射),SR 140333的低效对映体,无活性。5. 在对照动物中,与溶剂相比,蜂毒明肽(30纳摩尔/千克,静脉注射)增强了结肠推进(增加84%),并增加了收缩幅度(增加68%)。六甲铵(55微摩尔/千克,静脉注射加17微摩尔/小时输注)抑制了推进(抑制86%),并降低了收缩幅度(抑制49%)。SR 140333、SR 48968、MEN 11420、MEN 10627或联合给予SR 140333和MEN 10627均无作用。6. 在另一系列实验中,通过球囊导管装置在距肛门括约肌75毫米处保持等容条件下记录结肠收缩的平均幅度(静态模型)。在对照条件下,SR 140333和MEN 11420均未改变收缩幅度。在经阿托品预处理的豚鼠中,SR 140333和MEN 11420(0.1 - 1微摩尔/千克)剂量依赖性地降低了收缩幅度。在经蜂毒明肽和阿托品预处理的动物中,仅最高剂量(1微摩尔/千克)的SR 140333或MEN 11420显著降低了收缩幅度。阿托品(0.3 - 1微摩尔/千克)在经蜂毒明肽预处理的动物和对照动物中的抑制效力相似。7. 得出结论,在麻醉的豚鼠中,内源性速激肽通过NK(1)和NK(2)受体发挥作用,在促进蜂毒明肽诱发的远端结肠反射性推进活动中作为非胆碱能兴奋性神经递质。

相似文献

2
Tachykinin receptors mediate atropine-resistant rat duodenal reflex contractions in vivo.
Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):327-35. doi: 10.1007/BF00171064.
6
MEN 11420, a potent and selective tachykinin NK2 receptor antagonist in the guinea-pig and human colon.
Naunyn Schmiedebergs Arch Pharmacol. 1997 Nov;356(5):678-88. doi: 10.1007/pl00005105.

引用本文的文献

1
First translational consensus on terminology and definitions of colonic motility in animals and humans studied by manometric and other techniques.
Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):559-579. doi: 10.1038/s41575-019-0167-1. Epub 2019 Jul 11.
2
Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.
Br J Pharmacol. 2004 Apr;141(8):1249-63. doi: 10.1038/sj.bjp.0705751. Epub 2004 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验